Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,714 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Peer Support Dyads in Churches

NCT03463941
Conditions
Peer Support and Chronic Disease, Obesity, Type II Diabetes, Cardiovascular Disease, Cancer
Interventions
Peer Support Dyad Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

The HIV, Adipose Tissue Immunology, and Metabolism Study

NCT04451980
Conditions
Hiv, Diabetes Mellitus, Type 2
Interventions
Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection
Procedure · Radiation · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type 2 Diabetes
Interventions
Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more
Conditions
Overweight, Obesity, Type 2 Diabetes, Prediabetes
Interventions
Weight loss diet, Weight loss diet plus exercise
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
30 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Periodontal Disease
Interventions
Investigational Procedure
Procedure
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
30 Years to 70 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Iowa City, Iowa • Somerville, Massachusetts • Stony Brook, New York + 1 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Completed Not applicable Interventional Results available

Regimen Education and Messaging in Diabetes (REMinD)

NCT03185741
Conditions
Diabetes Mellitus, Type 2, Medication Adherence
Interventions
UMS Strategy, SMS Text Messaging
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Ortho-Cyclen, Dulaglutide
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Completed No phase listed Observational Accepts healthy volunteers

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

NCT02449213
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
35 Years to 65 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Adult Medication Study

NCT01779362
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Liraglutide, Glargine, Placebo
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
20 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
insulin aspart, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Fresno, California • New Orleans, Louisiana • Kansas City, Missouri + 6 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Enrolling by invitation Not applicable Interventional

PLAY2CONTROL Study

NCT07556679
Conditions
Type 2 Diabetes, Obesity & Overweight
Interventions
Nex Playground Activity Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
5 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Enlite Sensor
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Escondido, California • La Jolla, California + 4 more
Conditions
Amputation, Diabetes Mellitus, Type 2, Peripheral Artery Disease
Interventions
Physical Activity Behavior Change (PABC)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more